全球皮膚病治療藥物市場(到2017年為止)

全球皮膚病治療藥物市場(到2017年為止) 是由出版商GBI Research在2012年01月所出版的。 這份英文市場調查報告書包含Pages: 134 價格從美金3500起跳。

簡介

本報告提供全球皮膚病治療方法的相關市場分析，最新研究開發、全球及主要國家市場趨勢、主要疾患單位的詳細市場結構與動向、主要企業簡介、企業間合作的實情等資訊，為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場概況

• 簡介
  • 年度治療費用
  • 治療藥物的利用模式

第4章 各地區情形

• 地區區分
• 美國
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
• 歐洲(前5個國家)
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
• 日本
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式

第5章 各個治療藥物的市場概況

• 脫髮症治療藥物的全球市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
  • 治療的研究
  • 推動及阻礙市場要素
• 皰疹治療藥物的全球市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
  • 治療的研究
  • 推動及阻礙市場要素
• 乾癬治療藥物的全球市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
  • 治療的研究
  • 推動及阻礙市場要素
• 粉刺治療藥物的全球市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
  • 治療的研究
  • 推動及阻礙市場要素
• 酒糟性皮膚炎治療藥物的全球市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
  • 治療的研究
  • 推動及阻礙市場要素
• 異位性皮膚炎治療藥物的全球市場
  • 簡介
  • 收益
  • 年度治療費用
  • 治療藥物的利用模式
  • 治療的研究
  • 推動及阻礙市場要素

第6章 開發平台分析

• 簡介
  • 研究開發平台:脫髮症
  • 研究開發平台:皰疹
  • 研究開發平台:乾癬
  • 研究開發平台:粉刺
  • 研究開發平台:酒糟性皮膚炎
  • 研究開發平台:異位性皮膚炎
• 有前途的分子簡介
  • LAS 41002
  • Duac Low Dose
  • Clindamycin + Tretinoin

第7章 競爭環境

• 市場佔有率分析
• 主要企業簡介
  • Centocor Ortho Biotech Inc
  • Amgen
  • Abbott Laboratories
  • Merck & Co., Inc.
  • Novartis AG
  • GlaxoSmithKline plc.

第8章 策略性企業整合

• 企業合併·收購
• 授權合約

第9章 附錄

圖表一覽

目錄

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenue by geographical landscape for the indications covered in the report, and annual cost of treatment are forecast until 2017 for the key geographies and leading therapeutic segments. The report provides branded and generics segmentation in the therapeutic landscape segment. The report analyzes the competitive benchmarking for the leading companies and the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the dermatology market will continue to grow at a steady CAGR during the period 2010-2017 compared to the CAGR during 2002-2010. The growth is primarily driven by the increase in the psoriasis market, which is attributed to increased competition among the existing products and a strong pipeline with more emerging therapies. Acne is the largest market segment, accounting for 28.7% of the total dermatology therapeutics market, followed by psoriasis (26.4%), rosacea (14.9%) and atopic dermatitis (9%). The global dermatology market is a highly fragmented market with large players facing tough competition. The forthcoming patent expiries of major drugs have increased the competition, further driving the consolidation. The increasing pressure has also driven companies to enter into licensing agreements to allow them to expand their product portfolio and improve competitive positions in the market.

Scope

• Annualized market data for the dermatology therapeutics market from 2002 to 2010, forecast forward to 2017.
• Analysis of the leading therapeutic segments. These include acne, psoriasis, atopic dermatitis, rosacea and herpes.
• Analysis of the dermatology therapeutics markets in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
• Market characterization of the dermatology therapeutics market including market size, annual cost of treatment, and treatment usage patterns.
• Key drivers and barriers that have a significant impact on the market.
• Coverage of pipeline molecules in various phases of drug development.
• Competitive benchmarking of leading companies. Key companies studied in this report are Centocor Ortho Biotech Inc, Amgen Inc, Abbott Laboratories, Merck & Co., Inc, Novartis AG and GlaxoSmithKline Plc.
• Key M&A activities and licensing agreements up to June 2011 in the global dermatology therapeutics market.

Reasons to buy

• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
• Develop key strategic initiatives by understanding the key focus areas of the leading companies.
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

GBI Research, the leading business intelligence provider, has released its latest research, “Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. It provides treatment usage patterns, revenue, annual cost of treatment and forecasts to 2017 for the key geographies and leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and it analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Herpes (simplex and zoster) pipeline portfolio is weak with 26 molecules under research and development. Seven molecules are under Phase III clinical studies, while five molecules have first in class mechanism of action among all pipeline molecules. Occurrence of headache, nausea, dizziness and abdominal is another common problem among patient population that is being treated with present therapies. Hence there is high demand for synthesizing safer drugs.

The herpes therapeutics has strong market for some antivirals such as Zovirax (acyclovir), Famvir (famciclovir), Zostavax (Herpes Zoster Vaccine) and Valtrex (valacyclovir). These drugs contribute for more than $1.2 billion of global herpes therapeutics market. Large sector of the market is shared by generics that are having low prices which demands high first in class outputs from research and development side to strengthen the market.

The herpes therapeutics market will basically grow due to increasing awareness about the disease and increasing trends for their treatment. The number of prescribed patients will increase from 2010 to 2107 with a CAGR of 7.1%, indirectly increasing revenues for herpes therapeutics market. Hence negative impact from weak pipeline molecules will be countered by increasing trend of prescription population.

From 2002, the market grew at a Compound Annual Growth Rate (CAGR) of 7.2% to reach $16.3 billion in 2010. Psoriasis was one of the fastest growing segments. This growth is primarily attributed to increased competition among the existing products and a strong pipeline with more emerging therapies. The current market is crowded with biologics and topical treatments for psoriasis. The pipeline is strong with biologics and several other treatments for mild to moderate psoriasis. The psoriasis market is expected to reap large revenues with the increased uptake of biologics and the increased awareness of the disease in patients leading to increased treatment seeking rates at the early stages of the disease.

In the dermatology sector, most companies coordinate their Research and Development (R&D) activities to constantly expand their product pipeline with innovative drugs. Though there is a consistent and continuous threat from generics and other alternatives, companies in the dermatology sector are not reluctant to invest in R&D and are focused on offering new products to the market. There are about 543 drugs in the dermatology pipeline.

1. Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Dermatology Therapeutics Market to 2017 - Introduction

• 2.1 Introduction
• 2.2 GBI Research Report Guidance

3. Dermatology Therapeutics Market to 2017 - Market Overview

• 3.1 Introduction
  • 3.1.1 Annual Cost of Treatment
  • 3.1.2 Treatment Usage Pattern

4. Dermatology Therapeutics Market to 2017 - Geographical Landscape

• 4.1 Geographical Break-up
• 4.2 The US
  • 4.2.1 Revenue
  • 4.2.2 Annual Cost of Treatment
  • 4.2.3 Treatment Usage Pattern
• 4.3 Top Five Countries in Europe
  • 4.3.1 Revenue
  • 4.3.2 Annual Cost of Treatment
  • 4.3.3 Treatment Usage Pattern
• 4.4 Japan
  • 4.4.1 Revenue
  • 4.4.2 Annual Cost of Treatment
  • 4.4.3 Treatment Usage Pattern

5. Dermatology Therapeutics Market to 2017 - Therapeutic Landscape

• 5.1 Global Alopecia Therapeutics Market
  • 5.1.1 Introduction
  • 5.1.2 Revenue
  • 5.1.3 Annual Cost of Treatment
  • 5.1.4 Treatment Usage Pattern
  • 5.1.5 Treatment Algorithm
  • 5.1.6 Drivers and Restraints for the Alopecia Market
• 5.2 Global Herpes Therapeutics Market: Market Characterization
  • 5.2.1 Introduction
  • 5.2.2 Revenue
  • 5.2.3 Annual Cost of Treatment
  • 5.2.4 Treatment Usage Pattern
  • 5.2.5 Treatment Algorithm
  • 5.2.6 Drivers and Restraints for the Herpes Therapeutics Market
• 5.3 Global Psoriasis Therapeutics Market
  • 5.3.1 Introduction
  • 5.3.2 Revenue
  • 5.3.3 Annual Cost of Treatment
  • 5.3.4 Treatment Usage Pattern
  • 5.3.5 Treatment Algorithm
  • 5.3.6 Drivers and Restraints for Psoriasis Market
• 5.4 Global Acne Therapeutics Market
  • 5.4.1 Introduction
  • 5.4.2 Revenue
  • 5.4.3 Annual Cost of Treatment
  • 5.4.4 Treatment Usage Pattern
  • 5.4.5 Treatment Algorithm
  • 5.4.6 Drivers and Restraints for the Acne Therapeutics Market
• 5.5 Global Rosacea Disease Therapeutics Market
  • 5.5.1 Introduction
  • 5.5.2 Revenue
  • 5.5.3 Annual Cost of Treatment
  • 5.5.4 Treatment Usage Pattern
  • 5.5.5 Treatment Algorithm
  • 5.5.6 Drivers and Restraints for the Rosacea Therapeutics Market
• 5.6 Global Atopic Dermatitis Therapeutics Market
  • 5.6.1 Introduction
  • 5.6.2 Revenue
  • 5.6.3 Annual Cost of Treatment
  • 5.6.4 Treatment Usage Pattern
  • 5.6.5 Treatment Algorithm
  • 5.6.6 Drivers and Restraints for the Atopic Dermatitis Therapeutics Market

6. Dermatological Therapeutics Market to 2017 - Pipeline Analysis

• 6.1 Introduction
  • 6.1.1 Research and Development Pipeline - Alopecia
  • 6.1.2 Research and Development Pipeline - Herpes
  • 6.1.3 Research and Development Pipeline - Psoriasis
  • 6.1.4 Research and Development Pipeline - Acne
  • 6.1.5 Research and Development Pipeline - Rosacea
  • 6.1.6 Research and Development Pipeline - Atopic Dermatitis
• 6.2 Profiles of Promising Molecules in the Dermatology Therapeutics Market
  • 6.2.1 LAS 41002
  • 6.2.2 Duac Low Dose
  • 6.2.3 Clindamycin + Tretinoin

7. Dermatology Therapeutics Market to 2017 - Competitive Landscape

• 7.1 Market Share Analysis - Dermatological Disorders
• 7.2 Competitive Profiling
  • 7.2.1 Centocor Ortho Biotech Inc
  • 7.2.2 Amgen
  • 7.2.3 Abbott Laboratories
  • 7.2.4 Merck & Co., Inc.
  • 7.2.5 Novartis AG
  • 7.2.6 GlaxoSmithKline plc.

8. Dermatology Therapeutics Market to 2017 - Strategic Consolidations

• 8.1 Mergers and Acquisitions
  • 8.1.1 Deals by Indication
  • 8.1.2 Deals by Geography
  • 8.1.3 Deals by Value
  • 8.1.4 Major M&A Deals
• 8.2 Licensing Agreements
  • 8.2.1 Deals by Indication
  • 8.2.2 Deals by Geography
  • 8.2.3 Deals by Value
  • 8.2.4 Major Licensing Agreements

9. Dermatology Therapeutics Market to 2017 - Appendix

• 9.1 Market Definitions
• 9.2 Abbreviations
• 9.3 Research Methodology
  • 9.3.1 Coverage
  • 9.3.2 Secondary Research
  • 9.3.3 Primary Research
• 9.4 Therapeutic Landscape
  • 9.4.2 Market Size by Geography
• 9.5 Geographical Landscape
• 9.6 Pipeline Analysis
• 9.7 Competitive Landscape
  • 9.7.1 Expert Panel Validation
• 9.8 Contact Us
• 9.9 Disclaimer
• 9.10 Sources

• Table 1: Dermatology Therapeutics Market, Global, Revenue ($bn), 2002-2010
• Table 2: Dermatology Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
• Table 3: Dermatology Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
• Table 4: Dermatology Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 5: Dermatology Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 6: Dermatology Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 7: Dermatology Therapeutics Market, Revenue by Geography ($m), 2002-2010
• Table 8: Dermatology Therapeutics Market, Revenue by Geography ($m), 2010-2017
• Table 9: Dermatology Therapeutics Market, The US, Revenue ($m), 2002-2010
• Table 10: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2010-2017
• Table 11: Dermatology Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010
• Table 12: Dermatology Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017
• Table 13: Dermatology Therapeutics Market, The US, Treatment Usage Pattern (million), 2002-2010
• Table 14: Dermatology Therapeutics Market, The US, Treatment Usage Pattern (million), 2010-2017
• Table 15: Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2010
• Table 16: Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue Forecasts ($m), 2010-2017
• Table 17: Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue by Country ($m), 2002-2010
• Table 18: Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue by Country ($m), 2010-2017
• Table 19: Dermatology Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2002-2010
• Table 20: Dermatology Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2010-2017
• Table 21: Dermatology Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2002-2010
• Table 22: Dermatology Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2010-2017
• Table 23: Dermatology Therapeutics Market, Japan, Revenue ($m), 2002-2010
• Table 24: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2010-2017
• Table 25: Dermatology Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010
• Table 26: Dermatology Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017
• Table 27: Dermatology Therapeutics Market, Japan, Treatment Usage Pattern (million), 2002-2010
• Table 28: Dermatology Therapeutics Market, Japan, Treatment Usage Pattern (million), 2010-2017
• Table 29: Alopecia Therapeutics Market, Global, Revenue ($bn), 2002-2010
• Table 30: Alopecia Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
• Table 31: Alopecia Therapeutics Market, Global, Revenue by Geography ($m), 2002-2010
• Table 32: Alopecia Therapeutics Market, Global, Revenue by Geography ($m), 2010-2017
• Table 33: Alopecia Therapeutics Market, Global, Annual Cost of Treatment($), 2002-2010
• Table 34: Alopecia Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017
• Table 35: Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 36: Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 37: Herpes Therapeutics Market, Global, Revenue ($bn), 2002-2010
• Table 38: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Table 39: Herpes Therapeutics Market, Global, Revenue by Geography ($m), 2002-2010
• Table 40: Herpes Therapeutics Market, Global, Revenue by Geography ($m), 2010-2017
• Table 41: Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
• Table 42: Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 43: Herpes Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 44: Herpes Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 45: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002-2010
• Table 46: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
• Table 47: Psoriasis Therapeutics Market, Global, Revenue by Geography ($m), 2002-2010
• Table 48: Psoriasis Therapeutics Market, Global, Revenue by Geography ($m), 2010-2017
• Table 49: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
• Table 50: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 51: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 52: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 53: Acne Therapeutics Market, Global, Revenue ($bn), 2002-2010
• Table 54: Acne Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
• Table 55: Acne Therapeutics Market, Global, Revenue by Geography ($m), 2002-2010
• Table 56: Acne Therapeutics Market, Global, Revenue by Geography ($m), 2010-2017
• Table 57: Acne Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
• Table 58: Acne Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 59: Acne Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 60: Acne Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 61: Rosacea Therapeutics Market, Global, Revenue ($bn), 2002-2010
• Table 62: Rosacea Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
• Table 63: Rosacea Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
• Table 64: Rosacea Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
• Table 65: Rosacea Therapeutics Market, Global, Annual Cost of Treatment, ($) 2002-2010
• Table 66: Rosacea Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 67: Rosacea Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 68: Rosacea Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 69: Atopic Dermatitis Therapeutics Market, Global, Revenue ($m), 2002-2010
• Table 70: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017
• Table 71: Atopic Dermatitis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
• Table 72: Atopic Dermatitis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
• Table 73: Atopic Dermatitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
• Table 74: Atopic Dermatitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
• Table 75: Atopic Dermatitis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010
• Table 76: Atopic Dermatitis Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017
• Table 77: Alopecia Therapeutics Market, Global, Pipeline Analysis, Phase II, May 2011
• Table 78: Alopecia Therapeutics Market, Global, Pipeline Analysis, Preclinical, May 2011
• Table 79: Herpes Therapeutics Market, Global, Pipeline Analysis, Phase III, May 2011
• Table 80: Herpes Therapeutics Market, Global, Pipeline Analysis, Phase II, May 2011
• Table 81: Herpes Therapeutics Market, Global, Pipeline Analysis, Phase I, May 2011
• Table 82: Herpes Therapeutics Market, Global, Pipeline Analysis, Preclinical, May 2011
• Table 83: Psoriasis Therapeutics Market, Global, Pipeline Analysis, NDA Filed, May 2011
• Table 84: Psoriasis Therapeutics Market, Global, Pipeline Analysis, Phase III, May 2011
• Table 85: Psoriasis Therapeutics Market, Global, Pipeline Analysis, Phase II, May 2011
• Table 86: Psoriasis Therapeutics Market, Global, Pipeline Analysis, Phase I, May 2011
• Table 87: Psoriasis Therapeutics Market, Global, Pipeline Analysis, Preclinical, May 2011
• Table 88: Acne Therapeutics Market, Global, Pipeline Analysis, NDA Filed, May 2011
• Table 89: Acne Therapeutics Market, Global, Pipeline Analysis, Phase III, May 2011
• Table 90: Acne Therapeutics Market, Global, Pipeline Analysis, Phase II, May 2011
• Table 91: Acne Therapeutics Market, Global, Pipeline Analysis, Phase I, May 2011
• Table 92: Acne Therapeutics Market, Global, Pipeline Analysis, Preclinical, May 2011
• Table 93: Rosacea Therapeutics Market, Global, Pipeline Analysis, Phase III, May 2011
• Table 94: Rosacea Therapeutics Market, Global, Pipeline Analysis, Phase II, May 2011
• Table 95: Rosacea Therapeutics Market, Global, Pipeline Analysis, Phase I, May 2011
• Table 96: Rosacea Therapeutics Market, Global, Pipeline Analysis, Preclinical, May 2011
• Table 97: Atopic Dermatitis Therapeutics Market, Global, Pipeline Analysis, NDA Filed, May 2011
• Table 98: Atopic Dermatitis Therapeutics Market, Global, Pipeline Analysis, Phase III, May 2011
• Table 99: Atopic Dermatitis Therapeutics Market, Global, Pipeline Analysis, Phase II, May 2011
• Table 100:Atopic Dermatitis Therapeutics Market, Global, Pipeline Analysis, Phase I, May 2011
• Table 101:Atopic Dermatitis Therapeutics Market, Global, Pipeline Analysis, Preclinica, May 2011

• Figure 1: Dermatology Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Figure 2: Dermatology Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 3: Dermatology Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 4: Dermatology Therapeutics Market, Revenue by Geography ($m), 2002-2017
• Figure 5: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2002-2017
• Figure 6: Dermatology Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017
• Figure 7: Dermatology Therapeutics Market, The US, Treatment Usage Pattern (million), 2002-2017
• Figure 8: Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue Forecasts ($m), 2002-2017
• Figure 9: Dermatology Therapeutics Market, Top Five Countries in Europe, Revenue by Country ($m), 2002-2017
• Figure 10: Dermatology Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2002-2017
• Figure 11: Dermatology Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2002-2017
• Figure 12: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2017
• Figure 13: Dermatology Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017
• Figure 14: Dermatology Therapeutics Market, Japan, Treatment Usage Pattern (million), 2002-2017
• Figure 15: Alopecia Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Figure 16: Alopecia Therapeutics Market, Global, Revenue by Geography ($m), 2002-2017
• Figure 17: Alopecia Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017
• Figure 18: Alopecia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 19: Alopecia Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 20: Alopecia Therapeutics Market, Global, Treatment Algorithm
• Figure 21: Alopecia Therapeutics Market, Drivers and Barriers. 2010-2017
• Figure 22: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Figure 23: Herpes Therapeutics Market, Global, Revenue by Geography ($m), 2002-2017
• Figure 24: Herpes Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017
• Figure 25: Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 26: Herpes Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 27: Herpes Therapeutics Market, Global, Treatment Algorithm
• Figure 28: Herpes Therapeutics Market, Drivers and Barriers, 2010-2017
• Figure 29: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Figure 30: Psoriasis Therapeutics Market, Global, Revenue by Geography ($m), 2002-2017
• Figure 31: Psoriasis Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017
• Figure 32: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 33: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 34: Psoriasis Therapeutics Market, Global, Treatment Algorithm
• Figure 35: Psoriasis Therapeutics Market, Drivers and Barriers, 2010-2017
• Figure 36: Acne Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Figure 37: Acne Therapeutics Market, Global, Revenue by Geography ($m), 2002-2017
• Figure 38: Acne Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017
• Figure 39: Acne Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 40: Acne Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 41: Acne Therapeutics Market, Global, Treatment Algorithm
• Figure 42: Acne Therapeutics Market, Drivers and Barriers, 2010-2017
• Figure 43: Rosacea Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
• Figure 44: Rosacea Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
• Figure 45: Rosacea Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017
• Figure 46: Rosacea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 47: Rosacea Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 48: Rosacea Therapeutics Market, Global, Treatment Algorithm
• Figure 49: Rosacea Therapeutics Market, Drivers and Barriers, 2010-2017
• Figure 50: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017
• Figure 51: Atopic Dermatitis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
• Figure 52: Atopic Dermatitis Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017
• Figure 53: Atopic Dermatitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
• Figure 54: Atopic Dermatitis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
• Figure 55: Atopic Dermatitis Therapeutics Market, Global, Treatment Algorithm
• Figure 56: Atopic Dermatitis Therapeutics Market, Drivers and Barriers, 2010-2017
• Figure 57: Dermatological Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
• Figure 58: Dermatology Market, Global, Market Share of Top Manufacturers, Jun 2011
• Figure 59: Dermatology Therapeutics Market, Global, SWOT - Centocor Ortho Biotech Inc, 2010
• Figure 60: Dermatology Therapeutics Market, Global, SWOT - Amgen, 2010
• Figure 61: Dermatology Therapeutics Market, Global, SWOT - Abbott Laboratories, 2010
• Figure 62: Dermatology Therapeutics Market, Global, SWOT - Merck, 2010
• Figure 63: Dermatology Therapeutics Market, Global, SWOT - Novartis AG, 2010
• Figure 64: Dermatology Therapeutics Market, Global, SWOT - GlaxoSmithKline, 2010
• Figure 65: Dermatological Disorders Therapeutics Market, M&A Deals by Indication (%), Jun 2011
• Figure 66: Dermatology Therapeutics Market, Major Deals by Geography (%), Jun 2011
• Figure 67: Dermatological Disorders Therapeutics Market, Deals by Value (%), Jun 2011
• Figure 68: Dermatology Therapeutics Market, Global, Licensing Agreements by Indication, Jun 2011
• Figure 69: Dermatological Therapeutics Market, Global, Licensing Agreements by Geography, Jun 2011
• Figure 70: Dermatological Disorders Therapeutics Market, Major Licensing Agreements by Deal Value (%), Jun 2011
• Figure 71: GBI Research Market Forecasting Model

相關商品

GBI Research發行的製藥相關市場調查報告書

學名藥的價格設定與回本:歐洲的緊縮政策與醫療費抑制的創新主導型製藥企業的壓力

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure

價格 : US $ 3500

出版日期 : 2012年04月

到2018年為止的開發業務受託機關 (CRO) 市場:研究能力強化和臨床開發計劃發展的官民合作關係

Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

價格 : US $ 3500

出版日期 : 2012年04月

到2018年為止的醫藥品受託製造廠商 (CMO) 市場:成本優勢和質量標準提高的信賴建立和對亞洲CMO的外國投資的促進

Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs

價格 : US $ 3500

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!